Research programme: immunoconjugated micelles - Eisai/Nanocarrier

Drug Profile

Research programme: immunoconjugated micelles - Eisai/Nanocarrier

Alternative Names: NC 6201

Latest Information Update: 29 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd; NanoCarrier
  • Developer NanoCarrier
  • Class Amides; Antineoplastics; Dipeptides; Immunoconjugates; Piperidines
  • Mechanism of Action Immunomodulators; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Apr 2016 Preclinical trials in Cancer in Japan (IV)
  • 14 Apr 2016 Pharmacodynamic and adverse events data froma preclinical study in cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top